The novel coronavirus is devious, persistent, and, according to some scientists, not even alive. But, as the world has had to learn, this tiny bundle of genetic material is a highly efficient invader. Each particle is armored with roughly 100 protrusions, or spikes, perfectly evolved to latch onto an enzyme on the surfaces of throat and lung cells, then slip into them and replicate millions and millions of times. Older coronaviruses, such as the one that caused severe acute respiratory syndrome, or SARS, operated similarly. The spikes of the new coronavirus, though, clasp human cells much more tightly, which appears to be one reason it spreads more easily. In the three months since scientists in China identified it, the coronavirus has infected more than 2.6 million people around the world and killed at least 180,000.
Neutralizing those spikes may be the best way to prevent the virus from harming its host. And among the most promising approaches to doing that is finding the right antibodies. Multiple companies are doing this, using antibodies from laboratory mice and recovered patients. Unlike existing medicines being tested on the virus—such as hydroxychloroquine, the malaria drug controversially touted by President Trump, and remdesivir, an antiviral compound originally developed by Gilead Sciences Inc. to fight Ebola—antibody drugs are being designed specifically to disable the new virus where it’s most vulnerable. They’re taking advantage of sophisticated technologies developed over the past two decades to create exquisitely targeted medicines. If they work, the therapies could be used in two crucial ways: to treat those already infected and, in the absence of a vaccine, as a short-term prophylactic for those at high risk.
Esta historia es de la edición April 27, 2020 de Bloomberg Businessweek.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición April 27, 2020 de Bloomberg Businessweek.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers